Benzinga | Jan 29, 2021 08:55AM EST

Wedbush Downgrades Lexicon Pharmaceuticals to Neutral, Raises Price Target to $8

Wedbush analyst Liana Moussatos downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) from Outperform to Neutral and raises the price target from $2 to $8.